The Bruton Tyrosine Kinase (BTK) Inhibitors Market revolves around small‑molecule drugs that inhibit Bruton’s tyrosine kinase, a key signaling enzyme in B‑cell receptor pathways. By blocking BTK activity, these agents disrupt survival and proliferation signals in malignant B cells, making BTK inhibitors central to the treatment of several B‑cell malignancies and, increasingly, certain...